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Epstein–Barr virus (EBV) has been recently shown to be co-present with high-risk 
human papillomaviruses (HPVs) in human cervical cancer; thus, these oncoviruses 
play an important role in the initiation and/or progression of this cancer. Accordingly, 
our group has recently viewed the presence and genotyping distribution of high-risk 
HPVs in cervical cancer in Syrian women; our data pointed out that HPVs are present 
in 42/44 samples (95%). Herein, we aim to explore the co-prevalence of EBV and 
high-risk HPVs in 44 cervical cancer tissues from Syrian women using polymerase 
chain reaction, immunohistochemistry, and tissue microarray analyses. We found that 
EBV and high-risk HPVs are co-present in 15/44 (34%) of the samples. However, 
none of the samples was exclusively EBV-positive. Additionally, we report that the co- 
expression of LMP1 and E6 genes of EBV and high-risk HPVs, respectively, is asso-
ciated with poorly differentiated squamous cell carcinomas phenotype; this is accom-
panied by a strong and diffuse overexpression of Id-1 (93% positivity), which is an 
important regulator of cell invasion and metastasis. These data imply that EBV and 
HPVs are co-present in cervical cancer samples in the Middle East area including Syria 
and their co-presence is associated with a more aggressive cancer phenotype. Future 
investigations are needed to elucidate the exact role of EBV and HPVs cooperation in 
cervical carcinogenesis.
Keywords: epstein–Barr virus, high-risk human papillomaviruses, cervical cancer, syrian women, cancer 
phenotype
inTrODUcTiOn
Cervical cancer is the fourth most common malignancy among women worldwide with approxi-
mately 528,000 new cases and 266,000 deaths each year estimated by the World Health Organization. 
Notably, most cervical cancer deaths (87%) occur in the developing countries. Currently, it is well 
known that the majority of cancer deaths are the result of metastasis, either directly due to tumor 
involvement of critical organs or indirectly due to therapeutic resistance and the inability of avail-
able therapy to control tumor progression (1). On the other hand, it is estimated that approximately 
TaBle 2 | Epstein–Barr virus (EBV) and high-risk HPVs detection in human 
cervical carcinomas.
cervical cancer samples (n = 44) hPV statusa eBV statusa
Positive 42/44 (95%) 15/44 (34%)
Negative 2/44 (5%) 29/44 (66%)
aBased on PCR and immunohistochemistry (IHC) assays.
The co-incidence of these viruses was found in 15 (34%) samples out of 44 examined 
by PCR and IHC using specific primers for LMP1, EBNA1, and E6/E7 genes of 
EBV and high-risk HPVs types (16, 18, 31, 33, 35, 45, 51, 52, and 58) as well as 
monoclonal antibodies for LMP1 and E6, as described in the Section “Materials and 
Methods.”
TaBle 1 | The specific primer sets for LMP1 and EBNA1 genes of Epstein–Barr 
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20% of human cancers could be linked to oncoviruses infection 
including Epstein–Barr virus (EBV) and high-risk human papil-
lomaviruses (HPVs) especially types 16, 18, and 33 (2–4). EBV 
is a human gammaherpesvirus that infects more than 90% of the 
human adult population. Acute infection with EBV can cause 
infectious mononucleosis, and its latent state can lead to several 
types of human B-cell lymphomas and carcinomas, especially 
nasopharyngeal (5, 6).
Today, it is well established that high-risk of HPVs infections 
are important etiological factors in the development of human 
cervical cancer; as more than 96% of cervical cancers are positive 
for high-risk HPVs especially types 16, 18, 31, 33, and 35 world-
wide including the Middle East region (3, 7). Moreover, accu-
mulating evidence suggests that persistent infection with these 
viruses is necessary for cervical precursors to evolve into invasive 
carcinomas (8). Accordingly, we have explored the presence of 
high-risk HPVs in cervical cancer in Syrian women; our study 
revealed that 95% of our samples are positive for HPVs; more sig-
nificantly, we noted that the most frequent high-risk HPV types 
in Syrian women are 33, 16, 18, 45, 52, 58, and 35, in descending 
order. Furthermore, the expression of E6 onco-protein of high-
risk HPVs was found to be correlated with the overexpression of 
Id-1, which is a member of the inhibitor of DNA-binding (Id) 
proteins (9).
Id proteins constitute a family of highly preserved tran-
scriptional controllers that play critical roles during normal 
development and in the maintenance of homeostasis in human 
tissue (10). The main biological properties of Id proteins are 
inhibition of differentiation and conservation of the self-renewal 
capability and multipotency of stem cells (11). Id proteins are 
overexpressed in several human carcinomas (11, 12). More 
speci fically, Id-1 protein expression is directly involved in cancer 
initiation and/or progression in different types of human malig-
nancies including cervical (9, 13–15). On the other hand, it has 
been pointed out that LMP1 onco-protein of EBV upregulates 
Id-1 expression in nasopharyngeal immortalized and cancer 
cells (16, 17); however, the association between EBV onco-
proteins and Id-1 in human carcinomas, including cervical is 
not clear.
Earlier studies have indicated that EBV is frequently present 
in human cervical cancer tissues, suggesting EBV is associated 
with the development of cervical cancer (18). Moreover, it has 
been shown that the co-occurrence of EBV and high-risk HPVs 
in cervical tissues is more frequent in patients with high-grade 
squamous intraepithelial lesions in comparison with low-grade 
lesions (19). Thus, the presence of EBV in high-grade cervical 
lesions and cancer could suggest a possible cooperation between 
EBV and HPV in human cervical carcinogenesis; however, there 
are no studies regarding the co-presence of EBV and HPVs in the 
Middle East region.
Therefore, in this study, we evaluated the co-presence of these 
viruses and their association with Id-1 expression in cervical 
cancers in Syrian women. Our study pointed out that EBV and 
high-risk HPVs are co-present in 34% of our samples; more 
significantly, we noted that the co-incidence of these viruses is 
associated with poorly differentiated squamous cell carcinomas, 
which is accompanied with Id-1 overexpression.
MaTerials anD MeThODs
eBV and hPV Detection
Formalin fixed paraffin embedded blocks of cervical cancer were 
obtained from 44 Syrian patients with an average age of 57.25 years. 
Paraffin-embedded cervical tumor tissues were obtained from the 
Department of Pathology, Faculty of Medicine at the University 
of Aleppo, Syria. The specimens and data used in this study were 
approved by the Ethics Committee of the Faculty of Medicine of 
Aleppo University, Syria. Five micrograms of purified genomic 
DNA (Qiagen GmbH, Hilden, Germany), from each sample, was 
analyzed for EBV and HPV by polymerase chain reaction (PCR) 
using specific primers for LMP1 and EBNA1 as well as E6/E7 of 
HPV types 16, 18, 31, 33, 35, 45, 51, 52, and 58, while, primers for 
GAPDH gene were used as an internal control (Tables 1 and 2). 
This analysis was performed as previously described by our 
group (9, 20).
Tissue Microarray (TMa)
The TMA construction was achieved as illustrated previously by 
our group (21, 22). Briefly, cervical cancer samples were embed-
ded into a virgin paraffin TMA block using a manual tissue arrayer 
(Beecher Instruments, Silver Spring, MD, USA). Each block was 
assembled without previous knowledge of linked clinical or 
pathological staging information. Two TMA cores of 1.0 mm in 
diameter were sampled from a cohort of 44 block tissue samples 
of Syrian patients diagnosed with cervical carcinomas. Afterward, 
4 µm sections were cut and stained with hematoxylin and eosin on 
the initial slides to verify the histological diagnosis. Next, slides 
of the completed blocks were used for immunohistochemistry 
(IHC) analysis.
FigUre 1 | (a,B) Images reflect the diffused and strong cervical cancer cell positivity for high-risk HPV (E6 onco-protein) (a) and Epstein–Barr virus (EBV) (LMP1 
protein) (B) (10× magnification); images (c,D) High-risk HPV and EBV positivity at higher magnification (D); as shown, EBV positivity is clear in some stromal cells 
and tumor infiltrating lymphocytes (arrows) (D) (20× magnification).
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immunohistochemistry
Immunohistochemistry procedures examining the expression of 
LMP1, E6, and Id-1 were carried out using standard practices as 
follows. To analyze the protein expression patterns of LMP1, E6, 
and Id-1 in TMA slides, each one was deparaffinized in graded 
alcohol, rehydrated, and boiled (microwave) in 10 mM citrate buffer 
(pH 6.0) for antigen retrieval. Then, TMA slides were incubated for 
35 min at 37°C with primary monoclonal and polyclonal antibod-
ies for LMP1 of EBV and E6 of HPV as well as Id-1 (clone 1–4, 
clone C1P5, sc-488, from Dako and Calbiochem, Canada; as well as 
Santa Cruz Biotechnology, USA, respectively) using an automated 
immunostainer (Ventana Medical System, Tuscon, AZ, USA). The 
automated Ventana Medical System uses an indirect biotin–avidin 
system with a universal biotinylated immunoglobulin secondary 
antibody. Afterward, slides were counterstained with hematoxylin 
prior to mounting; staining procedures were completed according 
to the manufacturer’s recommendations. Negative controls were 
obtained by omitting specific primary antibody for LMP1 and E6 as 
well as specific blocking peptides from Santa Cruz Biotechnology 
and antibody for Id-1 protein. Following IHC, two independent 
observers examined all TMA slides. The tumors were considered 
positive for LMP1, E6, and Id-1 onco-proteins if cancer cells exhib-
ited positivity ≥1%. In case of LMP1 protein expression (EBV), we 
also evaluated the presence of viral infection in tumor-infiltrating 
lymphocytes and stromal cells. All IHC assays were evaluated using 
the Olympus light microscope (BX53); the slides were evaluated 
under magnifications 2×, 4×, 10×, and 20×.
statistical analysis
Statistical evaluations were done using IBM SPSS Statistics (ver-
sion 22; SPSS Inc., Chicago, IL, USA) and R. Data were calculated 
as nonparametric files. We utilized χ2 test with Yates correction 
to assess the significance of the association between cancer 
aggressiveness, Id-1 expression, and the co-presence of EBV and 
high-risk HPVs. Analysis of variance (ANOVA) test was used to 
analyze the differences among the group means.
resUlTs
We have recently explored the presence of high-risk HPVs in a 
cohort of 44 cervical cancer samples from Syrian women. Our pre-
vious study revealed that 42 (95.45%) of the 44 samples are high-
risk HPVs positive and all cases were infected with more than one 
HPV type. Moreover, these data revealed that the most prevalent 
high-risk HPV types are 33 (24+/44), 16 (21+/44), 18 (18+/44), 
45 (17+/44), 52 (13+/44), 58 (11+/44), 35 (9+/44), 51 (7+/44), 
and 31 (5+/44) (9) [for methodology used for PCR assay, please 
refer to Ref. (6)]. Herein, we further investigated the co-presence 
of EBV and high-risk HPVs in our 44 samples by PCR and IHC 
analysis using specific primers for LMP1 and EBNA1 as well as 
E6/E7 genes of EBV and HPVs, respectively (Table 1; Figure S1 in 
Supplementary Material) and monoclonal antibodies for LMP1 
and E6, as described in the Section “Materials and Methods.”
We found that 15 (34%) of the 44 samples are positive (≥1% 
positive cancer cells) for both EBV and high-risk HPVs (Table 2; 
Figures 1A–D). None of the cases was exclusively EBV positive 
while two cases were both HPV and EBV negative. In addition, 
we found no statistically significant association between the vari-
ous HPV types and EBV co-infection in cervical cancer samples 
(p > 0.05).
Next, we assessed the association between the co-presence 
of these viruses and tumor phenotype in our samples using 
FigUre 2 | A case of poorly differentiated (high-grade, non-keratinizing) cervical carcinoma: upper images highlight the presence of Epstein–Barr virus (EBV) (LMP1 
protein), high-risk HPV (E6 onco-protein), and a diffused Id-1 protein expression (10× magnification); lower images are respective high-power images (20× 
magnification); note the presence of EBV-positive tumor infiltrating lymphocytes (arrows).
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TMA methodology. Our data indicate that the co-expression of 
the LMP1 and E6 onco-proteins of EBV and high-risk HPVs, 
respectively, is associated with poorly differentiated squamous 
cell carcinoma form (Figure 2) in comparison with HPVs posi-
tive cases alone as well as negative cases for both, EBV and HPVs 
(p < 0.0001, respectively). On the other hand, we noted that the 
expression of LMP1 is located in cervical squamous cell carcino-
mas and frequently in stromal cells in addition to tumor infiltrat-
ing lymphocytes (Figure 1D); however, E6 of HPV, in general, 
is detected in cancer cells while the stromal and inflammatory 
cells (tumor infiltrating lymphocytes) are consistently negative 
(Figures 1D and 2).
Finally, we explored the association between the presence of 
EBV and HPVs with Id-1 overexpression in our Syrian samples by 
IHC. Using a 1% cutoff for positivity, Id-1 protein expression was 
observed in 41/44 cases (93%); diffuse and strong Id-1 expres-
sion (>50% cancer cells positive) was predominantly observed 
in high-grade (poorly differentiated) carcinomas (Figure 2). More-
over, we found that the co-expression of LMP1 and E6 (of EBV 
and HPV, respectively) is associated with diffuse and strong 
Id-1 overexpression in all invasive squamous cell carcinomas 
including high-grade carcinomas (p  =  0.001) (Figure  2). In 
particular, the association between HPV (E6) and diffuse Id-1 
(>50% cancer cells) was strong (p  <  0.0001). ANOVA test for 
overall significance confirmed the observed differences between 
the subgroups (HPV+/EBV+ vs. HPV+ alone) and Id-1 status 
(p < 0.0001).
DiscUssiOn
In this investigation, we explored, for the first time, the co-presence 
of EBV and high-risk HPVs in human cervical cancer and the role 
of this co-incidence with cancer phenotype in the conventional 
Middle East region. While, one study from North Africa pointed 
out that EBV and high-risk HPVs are co-present in 67.2% of cer-
vical cancer cases in Algerian women (23). Herein, it is important 
to highlight that infection with, at least one high-risk HPV alone, 
is necessary but not sufficient to provoke cervical cancer initia-
tion, additional oncovirus infection, and/or host genetic changes 
are required to drive neoplastic transformation and consequently 
lead to tumor formation (24, 25). In our investigation, we dem-
onstrated that EBV is co-present with high-risk HPVs in 34% 
of cervical cancer cases in the Syrian population. Accordingly, 
a recent meta-analysis study of 25 investigations regarding the 
presence of EBV in human cervical cancer revealed that EBV is 
present in 43.63% of samples from cancer patients in comparison 
with 19% of samples from healthy people or patients with cervical 
intraepithelial neoplasia grade 1 (CIN) (27.34%) or CIN grade 2/3 
(34.67%) (19). More significantly, co-infection with EBV and HPV 
is present in most of the cases, which display a similar phenotype 
of EBV infection (19); moreover, EBV infection is associated 
with differentiation (grade) of cervical epithelial cells (18). On 
the other hand, it has been pointed out that cervical carcinomas 
are four times more likely to occur among EBV-positive patients 
as compared with patients without EBV infection (19), which 
suggests a strong cooperation between EBV and HPVs in cervical 
carcinogenesis and possibly other human carcinomas (5). This 
concurs with our findings regarding the co-presence of EBV and 
high-risk HPVs and their association with cervical carcinomas 
in all positive cases, all of which are high-grade invasive cancers. 
Likewise, we have recently reported that EBV and high-risk HPVs 
are co-present in 32% of human breast cancer samples and their 
co-presence is associated with high-grade breast carcinomas and 
positive axillary lymph nodes (22).
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On the other hand, it is important to highlight that EBV onco-
proteins’ expression in cervical tissues is still controversial. Using 
in situ techniques for the detection of viral genomes or gene expres-
sions, few investigations showed that EBV is present in cervical 
carcinoma cells (23, 26–28). However, others studies reported 
EBV localization in infiltrating lymphoid cells next to cervical 
carcinomas and concluded that EBV infection could not play a 
specific role in cervical carcinogenesis (29, 30). Interestingly, our 
study revealed that the expression of LMP1 protein is present in 
cervical squamous cell carcinomas and occasionally in the stroma 
as well as in tumor infiltrating lymphocytes; LMP1 is co-present 
with E6 onco-protein of high-risk HPVs in cervical carcinoma 
cells in most cases.
Concerning the association between the two oncoviruses 
(EBV and HPV) and Id-1 gene, which is overexpressed in 
several human carcinomas, it has been reported that LMP1 
onco-protein of EBV upregulates the expression of Id-1 but not 
FoxO3a in human Hodgkin’s lymphoma cells (31). Likewise, in 
nasopharyngeal carcinoma, LMP1 induces an upregulation of 
Id-1 via FoxO3a inactivation (32). However, there are no studies 
regarding the EBV onco-proteins and Id-1 in human cervical 
cancer. In our present report, we demonstrate for the first time, 
the co-expression of LMP1 and E6 of EBV and high-risk HPVs, 
respectively, which is associated with Id-1 overexpression in 
human cervical cancer samples. However, herein, it is important 
to highlight that few investigations, including one from our lab, 
have pointed out that the presence of E6/E7 of high-risk HPVs is 
linked with Id-1 overexpression in human cervical cancer cells 
(9, 15, 33). More significantly, we have demonstrated that E6/
E7 onco-proteins of HPV type 16 bind and active Id-1 promotor 
in human breast cancer cells; in parallel, we reported that Id-1 
is the main regulator of cell invasion and metastasis induced by 
E6/E7 onco-proteins in these cancer cells (34). Accordingly, it is 
possible that EBV and high-risk HPV cooperate to upregulate 
the expression of Id-1 in human cervical cancer, which could 
enhance rapidly the progression of this cancer into invasive and 
metastatic form.
Nevertheless, further studies are necessary to clarify the role 
and pathogenesis of the co-presence of EBV and HPVs in human 
cervical carcinomas; especially since EBV and HPVs vaccines are 
presently under clinical trial and available, respectively (35–37). 
This is an important step, which could possibly limit cervical 
cancer initiation as well as its progression to a metastatic form, 
thereby decreasing cancer-related deaths especially in developing 
countries where cervical cancer is still the second major cause of 
death among women.
Finally, it is important to highlight that our investigation, in the 
Syrian population, is limited to a small number of cases located in a 
single region of Syria; therefore, it is essential to perform other stud-
ies of a larger number of cases from different regions in this country 
combined with several studies from the Middle East in general.
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FigUre s1 | Representative polymerase chain reaction reactions for LMP1 of 
Epstein–Barr virus (EBV) in four cervical cancer samples. Chronic B leukemia 
cells were used as a positive control (PC); human normal cervical cells were 
utilized as negative control (NC).
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